Cancer immune exclusion: breaking the barricade for a successful immunotherapy
- Autores
- Bruni, Sofia; Mercogliano, María Florencia; Mauro, Florencia Luciana; Cordo Russo, Rosalia Ines; Schillaci, Roxana
- Año de publicación
- 2023
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion.
Fil: Bruni, Sofia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Mercogliano, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Mauro, Florencia Luciana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina - Materia
-
EXTRACELLULAR MATRIX
IMMUNE EXCLUSION
MYELOID CELLS
PHYSICAL BARRIER
TUMOR INFILTRATING LYMPHOCYTES (TILS)
TUMOR MICROENVIRONMENT
TUMOR-ASSOCIATED MACROPHAGE (TAMS)
TUMOR-ASSOCIATED VASCULATURE - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/216096
Ver los metadatos del registro completo
id |
CONICETDig_192ae9439b81c6ed5c610e004ae61979 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/216096 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Cancer immune exclusion: breaking the barricade for a successful immunotherapyBruni, SofiaMercogliano, María FlorenciaMauro, Florencia LucianaCordo Russo, Rosalia InesSchillaci, RoxanaEXTRACELLULAR MATRIXIMMUNE EXCLUSIONMYELOID CELLSPHYSICAL BARRIERTUMOR INFILTRATING LYMPHOCYTES (TILS)TUMOR MICROENVIRONMENTTUMOR-ASSOCIATED MACROPHAGE (TAMS)TUMOR-ASSOCIATED VASCULATUREhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion.Fil: Bruni, Sofia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Mercogliano, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Mauro, Florencia Luciana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFrontiers Media2023-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/216096Bruni, Sofia; Mercogliano, María Florencia; Mauro, Florencia Luciana; Cordo Russo, Rosalia Ines; Schillaci, Roxana; Cancer immune exclusion: breaking the barricade for a successful immunotherapy; Frontiers Media; Frontiers in Oncology; 13; 3-2023; 1-252234-943XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fonc.2023.1135456info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1135456/fullinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:29:42Zoai:ri.conicet.gov.ar:11336/216096instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:29:43.216CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Cancer immune exclusion: breaking the barricade for a successful immunotherapy |
title |
Cancer immune exclusion: breaking the barricade for a successful immunotherapy |
spellingShingle |
Cancer immune exclusion: breaking the barricade for a successful immunotherapy Bruni, Sofia EXTRACELLULAR MATRIX IMMUNE EXCLUSION MYELOID CELLS PHYSICAL BARRIER TUMOR INFILTRATING LYMPHOCYTES (TILS) TUMOR MICROENVIRONMENT TUMOR-ASSOCIATED MACROPHAGE (TAMS) TUMOR-ASSOCIATED VASCULATURE |
title_short |
Cancer immune exclusion: breaking the barricade for a successful immunotherapy |
title_full |
Cancer immune exclusion: breaking the barricade for a successful immunotherapy |
title_fullStr |
Cancer immune exclusion: breaking the barricade for a successful immunotherapy |
title_full_unstemmed |
Cancer immune exclusion: breaking the barricade for a successful immunotherapy |
title_sort |
Cancer immune exclusion: breaking the barricade for a successful immunotherapy |
dc.creator.none.fl_str_mv |
Bruni, Sofia Mercogliano, María Florencia Mauro, Florencia Luciana Cordo Russo, Rosalia Ines Schillaci, Roxana |
author |
Bruni, Sofia |
author_facet |
Bruni, Sofia Mercogliano, María Florencia Mauro, Florencia Luciana Cordo Russo, Rosalia Ines Schillaci, Roxana |
author_role |
author |
author2 |
Mercogliano, María Florencia Mauro, Florencia Luciana Cordo Russo, Rosalia Ines Schillaci, Roxana |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
EXTRACELLULAR MATRIX IMMUNE EXCLUSION MYELOID CELLS PHYSICAL BARRIER TUMOR INFILTRATING LYMPHOCYTES (TILS) TUMOR MICROENVIRONMENT TUMOR-ASSOCIATED MACROPHAGE (TAMS) TUMOR-ASSOCIATED VASCULATURE |
topic |
EXTRACELLULAR MATRIX IMMUNE EXCLUSION MYELOID CELLS PHYSICAL BARRIER TUMOR INFILTRATING LYMPHOCYTES (TILS) TUMOR MICROENVIRONMENT TUMOR-ASSOCIATED MACROPHAGE (TAMS) TUMOR-ASSOCIATED VASCULATURE |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion. Fil: Bruni, Sofia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Mercogliano, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Mauro, Florencia Luciana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina |
description |
Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-03 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/216096 Bruni, Sofia; Mercogliano, María Florencia; Mauro, Florencia Luciana; Cordo Russo, Rosalia Ines; Schillaci, Roxana; Cancer immune exclusion: breaking the barricade for a successful immunotherapy; Frontiers Media; Frontiers in Oncology; 13; 3-2023; 1-25 2234-943X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/216096 |
identifier_str_mv |
Bruni, Sofia; Mercogliano, María Florencia; Mauro, Florencia Luciana; Cordo Russo, Rosalia Ines; Schillaci, Roxana; Cancer immune exclusion: breaking the barricade for a successful immunotherapy; Frontiers Media; Frontiers in Oncology; 13; 3-2023; 1-25 2234-943X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.3389/fonc.2023.1135456 info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1135456/full |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614304023707648 |
score |
13.070432 |